title: Burden of Severe Respiratory Syncytial Virus Disease Among 33-35 Weeks' Gestational Age Infants Born During Multiple Respiratory Syncytial Virus Seasons.
abstract: Moderate-late preterm infants, 33-35 weeks' gestational age (wGA), are at increased risk for respiratory syncytial virus hospitalization (RSVH). The objective of this study is to quantify the burden of RSVH in moderate-late preterm infants.
  
  
  
  A pooled analysis was conducted on RSVH from 7 prospective, observational studies in the Northern Hemisphere from 2000 to 2014. Infants' 33-35 wGA without comorbidity born during the respiratory syncytial virus season who did not receive respiratory syncytial virus immunoprophylaxis were enrolled. Data for the first confirmed RSVH during the season (+1 month) were analyzed. Incidence and hospitalization rate per 100 patient-seasons, intensive care unit admission and length of stay (LOS), oxygen support, mechanical ventilation and overall hospital LOS were assessed.
  
  
  
  The pooled analysis comprised 7,820 infants; 267 experienced a confirmed RSVH at a median age of 8.4 weeks. The crude pooled RSVH incidence rate was 3.41% and the rate per 100 patient-seasons was 4.52. Median hospital LOS was 5.7 days. A total of 22.2% of infants required intensive care unit admission for a median LOS of 8.3 days. A total of 70.4% received supplemental oxygen support for a median of 4.9 days, and 12.7% required mechanical ventilation for a median of 4.8 days.
  
  
  
  The burden of RSVH in moderate-late, 33-35 weeks' wGA preterm infants without comorbidities born during the viral season in Northern Hemisphere countries is substantial. Severe cases required prolonged and invasive supportive therapy.
authors.affiliation: From the *Departments of Pediatrics and Medicine, Emory University School of Medicine, Atlanta, GA; †Neonatology Service, Hospital Clinic, Institut d'Investigacions Biomediques August Pi Suñer (IDIBAPS), Barcelona, Spain; ‡Division of Pediatric Immunology and Infectious Diseases, University Medical Center Utrecht, Utrecht, The Netherlands; §Pediatrics and Neonatology Unit, Imola Hospital, Imola, Italy; ¶Department of Paediatrics, Trinity College and Coombe Women and Infants University Hospital, Dublin, Ireland; ‖Strategen Limited, Basingstoke, United Kingdom; **Global Pharmaceutical Research and Development, AbbVie Inc, North Chicago, IL; and ††Department of Pediatrics (Neonatal Division), McMaster University, Hamilton, Ontario, Canada.
authors.forename: Evan J
authors.initials: EJ
authors.lastname: Anderson
authors.forename: Xavier
authors.initials: X
authors.lastname: Carbonell-Estrany
authors.forename: Maarten
authors.initials: M
authors.lastname: Blanken
authors.forename: Marcello
authors.initials: M
authors.lastname: Lanari
authors.forename: Margaret
authors.initials: M
authors.lastname: Sheridan-Pereira
authors.forename: Barry
authors.initials: B
authors.lastname: Rodgers-Gray
authors.forename: John
authors.initials: J
authors.lastname: Fullarton
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Rouffiac
authors.forename: Pamela
authors.initials: P
authors.lastname: Vo
authors.forename: Gerard
authors.initials: G
authors.lastname: Notario
authors.forename: Fiona
authors.initials: F
authors.lastname: Campbell
authors.forename: Bosco
authors.initials: B
authors.lastname: Paes
mesh_terms: D005865:Gestational Age; D006760:Hospitalization / Q000706:statistics & numerical data; D006801:Humans; D015994:Incidence; D007223:Infant; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000453:epidemiology*; D007234:Infant, Premature; D018357:Respiratory Syncytial Virus Infections / Q000453:epidemiology*; D018113:Respiratory Syncytial Virus, Human